Rallybio (RLYB) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
2 Feb, 2026Opening remarks and agenda
The meeting was called to order by the Chairman, welcoming stockholders and outlining virtual participation procedures.
Only stockholders of record as of December 30, 2025, could participate and vote.
Specific resolutions to be voted on
Proposal 1 sought approval for an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between 1:5 and 1:20, to be determined by the Board.
Proposal 2 allowed for consideration of any other business that may properly come before the meeting or any adjournment.
Corporate governance
Broadridge Financial Services was appointed as Inspector of Elections, with Marlene Aguilar taking the oath.
The record date for voting was set as December 30, 2025, with 42,243,777 shares outstanding.
A quorum was established with 82.81% of voting power represented.
Latest events from Rallybio
- Merger forms a TCE therapeutics leader with $700M cash and a broad autoimmune disease pipeline.RLYB
M&A announcement2 Mar 2026 - Best-in-class efficacy, improved tolerability, and strong market demand drive $6B opportunity.RLYB
Status Update12 Jan 2026 - Rare disease pipeline advances, with key clinical milestones and new data expected in 2024.RLYB
7th Annual Evercore HealthCONx Conference11 Jan 2026 - Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.RLYB
Proxy Filing2 Jan 2026 - Lead rare disease programs advance with key data readouts and market expansion in 2024.RLYB
TD Cowen 45th Annual Healthcare Conference26 Dec 2025 - Shareholders will vote on a reverse stock split to maintain Nasdaq listing and enhance liquidity.RLYB
Proxy Filing23 Dec 2025 - Annual meeting to elect directors, ratify auditor, and review governance, compensation, and ESG.RLYB
Proxy Filing2 Dec 2025 - Lead program shift to RLYB116, with key clinical and preclinical data expected this year.RLYB
The Citizens JMP Life Sciences Conference 202521 Nov 2025 - Q3 2025 net income hit $16M after a $20M asset sale, with cash runway extended through 2027.RLYB
Q3 20256 Nov 2025